This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: C68 | Special Copayment Reduction: V193 | Copayment 5% (for 5 years from the date of cancer patient registration) |
| B. Synonyms | Urethral cancer, paraurethral gland cancer, periurethral gland carcinoma, Skene's gland carcinoma, urethral adenocarcinoma, urinary organ cancer, unspecified, Urethral carcinoma, Paraurethral gland carcinoma |
| C. Adult onset | Very high — occurs mainly in adults in their 60s–70s; pediatric occurrence is extremely rare |
Urethral cancer is a very rare disease even among urological malignancies, accounting for less than 1% of all cancers. The first systematic description of urethral cancer dates back to the late 19th century. In 1880, the Scottish anatomist Alexander J. C. Skene described a pair of glands located around the female urethra—later named Skene's glands (paraurethral glands)—and malignancies arising from these glands began to be reported very rarely. Paraurethral gland carcinoma arises from Skene's glands, which are regarded as the female homolog of the prostate, and is so rare that only about 15 cases have been reported in the literature.
The classification of urethral cancer has been gradually refined according to anatomical location and histologic type. From the early 20th century, it was confirmed that the histological composition of the urethra differs between men and women, and accordingly differences in the biological characteristics of anterior (distal) and posterior (proximal) urethral tumors were recognized. In the female urethra adenocarcinoma is common, while in men transitional cell carcinoma (urothelial carcinoma) is the most common, followed by squamous cell carcinoma. After the introduction of computed tomography (CT) and magnetic resonance imaging (MRI) in the 1970s–80s, accurate anatomical staging became possible, and from the 1990s combined-modality treatment—combining surgery, radiotherapy and chemotherapy—began to be standardized. In ICD-10, C68 covers malignant neoplasms of other urinary organs not belonging to the kidney (C64), renal pelvis (C65), ureter (C66) or bladder (C67), and is subdivided into C68.0 (urethra), C68.1 (paraurethral glands), C68.8 (overlapping sites) and C68.9 (unspecified).
The causes of urethral cancer and other urinary organ cancers are complex, with multiple risk factors acting in combination. Chronic irritation and inflammation is cited as the most important etiological factor. Urethral stricture, recurrent urinary tract infections, urogenital warts (condyloma) and sexually transmitted infections (STI)—particularly human papillomavirus (HPV) infection—are associated with the development of urethral cancer. Squamous cell carcinoma is closely associated with chronic inflammation, HPV type 16/18 infection and urethral stricture, while adenocarcinoma arises from Skene's glands or other glandular structures.
Sex differences are also distinct. Urethral adenocarcinoma is relatively common in women, while transitional cell carcinoma predominates in men. In male urethral cancer, urothelial carcinoma is common when it arises in the prostatic urethra, and squamous cell carcinoma is common when it arises in the penile and bulbar urethra (bulbomembranous urethra). Smoking, as with bladder cancer, is a risk factor for urethral cancer, and exposure to occupational carcinogens (aromatic amines) may also be involved. Radiation exposure increases the risk of secondary urinary tract cancer after pelvic radiotherapy. Paraurethral gland carcinoma arises from glandular cells of Skene's glands, the female homolog of the prostate, which secrete PSA (prostate-specific antigen); its etiology is still unclear, but the hormonal environment and local inflammation are presumed to play a role.
The genetics of urethral cancer differs by histologic type, sharing molecular abnormalities similar to those of bladder cancer and urothelial carcinoma. In transitional cell (urothelial) carcinoma, FGFR3 mutations, TP53 mutations, CDKN2A deletion and chromosome 9 abnormalities are frequently observed. FGFR3 mutations are associated with low-grade noninvasive urothelial carcinoma, and TP53 mutations are common in invasive high-grade cancer. In squamous cell carcinoma, inactivation of p53 and Rb by the E6/E7 proteins following HPV integration is the key oncogenic mechanism.
In adenocarcinoma, KRAS, CDKN2A, PIK3CA and TP53 mutations have been reported. Paraurethral gland carcinoma is characterized by PSA expression and partially overlaps with prostate cancer-related gene expression patterns. From a pharmacogenomic perspective, urethral cancer often follows bladder cancer treatment protocols, so the response to cisplatin-based chemotherapy may be related to ERCC1 expression. When MSI-H (microsatellite instability-high) or TMB-H (tumor mutational burden-high) is positive, an immune checkpoint inhibitor (pembrolizumab) is indicated. Recently, comprehensive gene panel testing using next-generation sequencing (NGS) has been used to identify treatable targets in rare urinary tract cancers.
Urethral cancer is extremely rare, accounting for less than 1% of all malignancies, with a reported annual incidence in Europe of about 1.3 per 1 million population. Incidence increases with age, and the male-to-female ratio is about 3:1, making it more common in men. However, urethral cancer in women tends to have greater histologic diversity and delayed diagnosis. Paraurethral gland carcinoma (Skene's gland carcinoma) is even rarer, with only a few dozen cases reported in the literature worldwide.
In Korea, urethral cancer is so rare that it is not tallied separately in National Cancer Information Center and National Cancer Center statistics, and the same is true of unspecified urinary tract cancer (C68.9). By race, there are reports that incidence is higher in Black than in White people, which may be related to differences in HPV infection rates and exposure to chronic urinary tract infection. At diagnosis, 40–50% are already locally advanced or have distant metastasis, owing to the nonspecific symptoms and diagnostic delay due to the rarity of the disease. The 5-year overall survival rate differs greatly by stage, being about 60–80% for early (T1) lesions and only 10–20% for advanced stages (T3-T4).
The pathogenesis of urethral cancer differs according to tissue of origin. In urothelial carcinoma (transitional cell carcinoma), DNA damage to urethral transitional epithelial cells is the starting point of the carcinogenic process. Smoking-related carcinogens (aromatic amines, polycyclic aromatic hydrocarbons) come into direct contact with urothelial cells, damage the DNA of mucosal cells and promote cell proliferation through activation of the FGFR3–RAS signaling pathway. TP53 inactivation inhibits cell cycle arrest and apoptosis, accelerating the accumulation of cancer cells.
In squamous cell carcinoma, squamous metaplasia of the normal urethral epithelium due to HPV infection or chronic irritation comes first. The HPV E6 protein degrades p53 and E7 degrades Rb, causing loss of cell cycle control, which gradually progresses from dysplasia → carcinoma in situ → invasive cancer. In adenocarcinoma, glandular metaplasia and dysplasia progress in the glandular cells of Skene's glands or the bladder neck, and activation of the KRAS–PI3K pathway has been proposed as the main molecular mechanism. With local invasion, it spreads directly to periurethral tissues, the corpus cavernosum and the bladder neck, followed by lymph node (inguinal, intrapelvic) metastasis; distant metastasis is most common in the lung, followed by the liver and bone.
Symptoms of urethral cancer vary with the location, size and stage of the tumor and are nonspecific early on, so diagnosis is often delayed. The most common initial symptoms are hematuria (including hematospermia) and urethral discharge. Distal tumors near the urethral meatus may present with urethral bleeding, a painless mass and dysuria, and in some cases can be observed directly by urethroscopy.
As the tumor progresses, voiding dysfunction (urinary retention, weak stream, frequency, urgency) appears, and complete obstruction can cause acute urinary retention. In women, symptoms such as a vulvar mass, vaginal discharge and vaginal bleeding may accompany it, so it may be mistaken for a gynecologic condition. Tumors arising in the proximal (posterior) urethra cause lower abdominal discomfort and pelvic pain in addition to voiding symptoms, and if a fistula to the rectum or bladder forms, complex symptoms such as fecaluria and pneumaturia may appear. When inguinal lymph node metastasis occurs, painless inguinal enlargement is observed. Systemic symptoms such as weight loss and fatigue appear in advanced stages.
On physical examination, a mass or induration around the urethral meatus may be palpated, and enlargement of Skene's glands around the female urethra may be found. In men, an indurated tumor may be found along the penile urethra, or there may be findings of invasion into the scrotum or perineum. Urethroscopy shows irregular mucosal elevation, hyperemia and a hemorrhagic mass. In advanced cases, inguinal lymphadenopathy and pelvic masses are palpated on internal examination (digital rectal examination, vaginal examination), and with distant metastasis, hepatomegaly and bone tenderness may appear.
For distal urethral tumors in women, the tumor may sometimes be seen directly on vulvar inspection. Urethral pain is not common but may appear when invasion is severe. When a urethral fistula forms, a fistula opening or exudate is seen on the perineal skin. With nerve invasion, sensory abnormalities in the distribution of the pudendal nerve may accompany it. Among radiological imaging, MRI is the most useful for evaluating urethral anatomy and tumor extent, clearly showing soft tissue invasion and lymph node metastasis.
Currently, there is no standardized population screening program for urethral cancer and other urinary organ cancers. This is because the extreme rarity of the disease makes population screening poorly cost-effective. Korea's National Cancer Screening Program does not include regular screening for bladder cancer or urethral cancer.
However, clinical attention is needed for some high-risk groups. In patients with recurrent chronic urinary tract infection or urethral stricture, patients who have received pelvic radiotherapy in the past, and patients with a history of high-risk HPV infection, immediate urethroscopy is recommended when symptoms occur. When urethral bleeding or voiding abnormalities persist, urine cytology and urine FISH testing may be performed, but because of low sensitivity they are used only as adjuncts. In those with a history of exposure to occupational carcinogens (benzidine, β-naphthylamine, etc.), regular monitoring for all urinary tract cancers is considered.
Diagnosis of urethral cancer proceeds in the steps of clinical suspicion → endoscopic/radiological evaluation → tissue biopsy. Urethroscopy (urethroscopy/cystourethroscopy) is the key diagnostic tool for directly visualizing the tumor and obtaining a tissue biopsy. Histopathological examination of the biopsy specimen confirms the histologic type (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma, small cell carcinoma, etc.) and degree of differentiation.
Magnetic resonance imaging (MRI) is the imaging test that best evaluates the anatomy of the urethra and is used as standard to evaluate the local extent of the tumor, invasion of the corpus cavernosum, sphincter invasion and lymph node metastasis. CT of the chest, abdomen and pelvis is used to evaluate distant metastasis. PET-CT (FDG) is used as an adjunct for staging lymph node and distant metastasis. Urine cytology is useful for diagnosing transitional cell carcinoma but has a high false-negative rate. In female paraurethral gland carcinoma, immunohistochemistry (PSA, PAP positive) helps differentiate it from metastatic cancer of prostatic origin. Staging applies the TNM (T1-T4/N0-N2/M0-M1) system, and tumors of the distal urethra (anterior 1/3) and proximal urethra (posterior 2/3) differ in prognosis and treatment strategy.
Treatment of urethral cancer is individualized according to stage, histologic type, anatomical location and patient condition. For low-stage distal urethral tumors (T1-T2 anterior urethra), surgical resection (partial distal urethrectomy) is the first-line treatment, and a relatively good prognosis can be expected when negative margins can be secured. In women, radiotherapy (external beam radiation or brachytherapy) for distal urethral cancer is used as an alternative to surgery.
For proximal urethral or advanced-stage (T3-T4) tumors, combined treatment with radical surgery (including cystourethrectomy and pelvic exenteration) and radiotherapy/chemotherapy is standard. As neoadjuvant chemotherapy, cisplatin-based regimens [cisplatin+5-FU, gemcitabine+cisplatin, etc.] are used, and surgery is performed after tumor shrinkage. Combined treatment has been shown to contribute to reduced recurrence and improved survival compared with single-modality treatment. In metastatic disease, cisplatin-based systemic chemotherapy is the main treatment, and when MSI-H or TMB-H is positive, the immune checkpoint inhibitor pembrolizumab (Keytruda) is indicated. Radiotherapy alone is also used in patients who cannot undergo surgery.
The prognosis of urethral cancer varies greatly by stage, histologic type and anatomical location. The overall 5-year survival rate is only 20–30% with single-modality treatment, but improves with combined treatment. Distal (anterior) urethral tumors have a significantly better prognosis than proximal (posterior) urethral tumors, with 5-year survival rates reaching 40–75%, whereas proximal urethral tumors reach only 10–40%. By histologic type, transitional cell carcinoma tends to respond better to radiotherapy and chemotherapy than squamous cell carcinoma or adenocarcinoma. T stage is the strongest prognostic factor, with 5-year survival of about 75% for T1, about 50% for T2 and 10–20% for T3-T4. Lymph node metastasis markedly worsens the prognosis.
Paraurethral gland carcinoma (Skene's gland carcinoma) has very few reported cases in the literature, so prognostic data are limited, but it is generally known to have a poor prognosis. Multicenter retrospective studies have confirmed that combined treatment with radiotherapy and chemotherapy improves overall survival compared with surgery alone. Recurrence occurs mainly locally or in lymph nodes, and distant metastasis is common in the lung, liver and bone.
The most effective methods of preventing urethral cancer are risk factor management and early detection. Smoking cessation is the most important behavioral change for reducing the risk of urinary tract cancers, including urethral cancer. HPV vaccination (Gardasil 9-valent, etc.) contributes to preventing HPV-related squamous cell carcinoma, and vaccination in adolescence is particularly effective. Practicing safe sex and using condoms can reduce the risk of HPV and other sexually transmitted infections.
Chronic urethral stricture and recurrent urinary tract infections should be treated actively at an early stage to minimize exposure to chronic inflammation. When there is occupational exposure to carcinogens, wearing protective equipment and improving the work environment are needed. Patients who have received pelvic radiotherapy in the past should be aware of the risk of secondary urinary tract cancer and undergo prompt urological evaluation if voiding abnormalities or hematuria occur. There is not yet a genetic screening test specific to urethral cancer, but genetic counseling and regular monitoring are recommended when there is a family history of hereditary cancer syndromes such as Li-Fraumeni syndrome or Lynch syndrome.